Glp 1 T 2d denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for glp1 t2d are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This GLP-1 for Type 2 Diabetes: Not FDA-Approved

This denial indicates Cigna determined that either the specific GLP-1 medication prescribed does not hold FDA approval for the treatment of type 2 diabetes, or that the particular use for which it was prescribed falls outside the drug's approved labeling. For a drug class that includes multiple FDA-approved agents for type 2 diabetes, this denial warrants careful scrutiny — it may reflect an error in Cigna's claims processing, a mismatch between the diagnosis code submitted and the approved indication, or an off-label use that your prescriber has sound clinical reasons for.

## Why It Is Appealable

Multiple GLP-1 receptor agonists carry FDA approval specifically for type 2 diabetes management. If your prescriber prescribed one of those agents for your type 2 diabetes diagnosis, the "not FDA-approved" classification is factually incorrect and should be reversed on appeal. If the denial reflects a genuinely off-label use, the appeal should document the clinical rationale and support from the applicable professional guideline organization, as off-label use of FDA-approved drugs is standard medical practice and must be considered under most plan terms.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full and fair internal review. Submit your written appeal by the deadline on the denial notice, attaching the FDA prescribing label as your primary exhibit.
• Request the specific basis: Cigna must explain the precise clinical criteria it applied. Request the full clinical review notes and the name of the reviewing clinician, which you are entitled to under ERISA.
• External review: After internal appeal, independent external review under ACA §2719 is available within approximately four months. External reviewers apply clinical standards, not just plan administrative policies.

## Documentation to Gather

1. FDA-approved prescribing label: The current, complete FDA label for the specific GLP-1 prescribed. The indication section is your primary rebuttal document — it either confirms FDA approval for type 2 diabetes or defines the scope of the approved indication. 2. Diagnosis records: Chart notes confirming your type 2 diabetes diagnosis with appropriate diagnostic coding, to ensure there is no claim-submission mismatch. 3. Prescriber letter: A letter from your prescribing physician confirming that the prescribed drug is being used within its FDA-approved indication (or, if off-label, the clinical rationale and guideline organization support for the use). 4. Applicable guideline organization reference: For any off-label component, a reference to the relevant professional organization's current treatment guidelines — without citing specific numeric thresholds. 5. Cigna's denial rationale in full: The complete denial letter, including any clinical policy number cited, so the appeal can address Cigna's exact stated basis.

## Criteria-Mapping Structure

Begin your appeal letter by quoting the FDA label's indication section verbatim. Directly below it, quote your diagnosis from the chart. Show that the two align. If Cigna cited a specific policy or clinical rationale in its denial, address it line by line. This side-by-side format makes the error in the denial immediately apparent to any clinical reviewer and creates a clear record if the case proceeds to external review.